Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Uterine sarcoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-24 of 24 for your search:
Start Over
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients with High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0277, NCI-2012-00249, CDR0000724874, IRCI 001, NCT01533207
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Paclitaxel and Vascular-Targeting Gene Therapeutic VB-111 in Treating Patients with Recurrent Uterine, Ovarian, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 19
Trial IDs: 11-418, NCI-2013-00628, VB-111-157, NCT01801215, NCT01711970
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARN-AR18-CT-101, NCI-2016-00136, NCT02052128
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Sapanisertib or Pazopanib Hydrochloride in Treating Patients with Locally Advanced or Metastatic Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091304, NCI-2015-01929, NCT02601209
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
PI3K/mTOR Inhibitor LY3023414 in Treating Patients with Recurrent or Persistent Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-079, NCI-2015-01639, NCT02549989
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RXDX-101-02, NCI-2015-01848, NCT02568267
Durvalumab and Tremelimumab in Treating Patients with Metastatic or Refractory Sarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-1071, NCI-2016-01178, NCT02815995
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients with Recurrent Stage I, III, or IV Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S15-01156, NCI-2016-01206, NCT02744898
Z-endoxifen Hydrochloride in Treating Patients with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0061, NCI-2013-01475, P10725, 110061, 8826, NCT01273168
Pazopanib Hydrochloride and Abexinostat in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11955, NCI-2012-01142, UCSF Protocol No. 11955, NCT01543763
ALT-803 in Treating Patients with Advanced Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: CITN-06-ALT-803, NCI-2013-01999, PCITN-06-ALT-803_A08PAMDREVW01, PCITN-06-ALT-803_A06PAMDREVW02, CA-ALT-803-01-13, NCT01946789
Selinexor, Paclitaxel, and Carboplatin in Treating Patients with Advanced Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-110, NCI-2014-02205, NCT02269293
NY-ESO-1-Specific T-cells in Treating Patients with Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2721.00, NCI-2014-02154, 2721, NCT02319824
Interferon Gamma-1b and Nivolumab in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU-084, NCI-2016-00138, NCT02614456
Metformin Hydrochloride and Doxycycline in Treating Patients with Localized Breast or Uterine Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16D.317, NCI-2016-00977, NCT02874430
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VX15-984-001, NCI-2016-01384, NCT02644278
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 11-02-064, NCI-2013-01225, 10-089, NCT01367301
Proton Beam Radiation Therapy in Treating Patients with Uterine or Cervical Cancer with Regional Lymph Node Metastases
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 10-269, NCI-2011-00894, NCT01600040
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-03-096, NCI-2013-01364, 13-014, NCT01958580
Surgery and Chemotherapy with or without Chemotherapy after Surgery in Treating Patients with Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
Status: Active
Phase: No phase specified
Type: Tissue collection/Repository, Treatment
Age: 18 and older
Trial IDs: 12316, NCI-2013-01948, 122035, 116613, 108303, 122550, NCT01970722
Start Over